FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Merck Sharp & Dohme Corp.

Cold storage system for storing pharmaceutical product containers

Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014025681809/11/14 new patent  Nano-suspension process
42014024428908/28/14Cold storage system for storing pharmaceutical product containers
52014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
62014023430108/21/14Modulation of pilr to treat immune disorders
72014023553708/21/14N-glycosylated insulin analogues
82014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
92014022722308/14/14Pegylated interleukin-10
102014022725008/14/14Stable formulations of antibodies to tslp
112014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
122014022729208/14/14Anti-mcam antibodies and associated methods of use
132014022002708/07/141d05 pcsk9 antagonists
142014022138308/07/14Cetp inhibitors
152014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
162014020656307/24/14Biomarkers for psoriasis
172014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
182014020664107/24/14Remedy
192014020666507/24/14Selective glycosidase inhibitors and uses thereof
202014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
212014020671507/24/14Preparation and use of compounds as protease inhibitors
222014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
232014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
242014017015406/19/14Engineered anti-il-23r antibodies
252014017065806/19/14Mammalian cytokines; related reagents
262014017143706/19/14Oxazole derivatives useful as inhibitors of faah
272014017145606/19/14Fused tricyclic compounds as mtor inhibitors
282014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
292014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
302014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
312014014744205/29/14Use of il-23 antagonists for treatment of infection
322014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
332014014095405/22/14Methods of modulating cytokine activity; related reagents
342014014101205/22/14Engineered anti-tslp antibody
352014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
362014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
372014014211505/22/14Inhibitors of the renal outer medullary potassium channel
382014014095405/22/14Methods of modulating cytokine activity; related reagents
392014014101205/22/14Engineered anti-tslp antibody
402014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
412014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
422014014211505/22/14Inhibitors of the renal outer medullary potassium channel
432014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
442014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
452014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
462014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
472014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
482014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
492014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
502014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
512014011291904/24/14Interleukin-10 antibodies
522014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
532014011291904/24/14Interleukin-10 antibodies
542014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
552014010588704/17/14Methods for modulating il-33 activity
562014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
572014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
582014010588704/17/14Methods for modulating il-33 activity
592014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
602014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
612014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
622014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
632014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
642014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
652014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
662014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
672014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
682014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
692014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
702014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
712014004574602/13/14Antidiabetic tricyclic compounds
722014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
732014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
742014003762702/06/14Modulation of pilr receptors to treat microbial infections
752014003894202/06/14Rorgammat inhibitors
762014003897002/06/14Bridged and fused antidiabetic compounds
772014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
782014003076001/30/14Pavec
792014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
802014003134901/30/14Inhibitors of the renal outer medullary potassium channel
812014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
822014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
832013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
842013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
852013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
862013032323912/05/13Modulation of pilr receptors to treat sepsis
872013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
882013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
892013032448312/05/13Mammalian cell surface antigens; related reagents
902013032461012/05/13Cathepsin cysteine protease inhibitors
912013032472812/05/13Process for the preparation of an orexin receptor antagonist
922013031635411/28/13Mammalian cytokine; related reagents
932013029627811/07/13Diazeniumdiolate derivatives
942013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
952013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
962013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
972013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
982013025167709/26/13Genetic markers associated with interferon-alpha response
992013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1002013023751809/12/13Novel compounds that are erk inhibitors
1012013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1022013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1032013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1042013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1052013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1062013021657508/22/13Recombinant subunit dengue virus vaccine
1072013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1082013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1092013021776608/22/13Formulations for cathepsin k inhibitors
1102013021657508/22/13Recombinant subunit dengue virus vaccine
1112013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1122013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1132013021776608/22/13Formulations for cathepsin k inhibitors
1142013020306008/08/13Mammalian genes; related reagents
1152013020306008/08/13Mammalian genes; related reagents
1162013018927807/25/13Antagonists of pcsk9
1172013018927807/25/13Antagonists of pcsk9
1182013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1192013015672906/20/13Mammalian receptor proteins; related reagents and methods
1202013015677106/20/13Fdf03 antibodies and uses thereof
1212013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1222013015672906/20/13Mammalian receptor proteins; related reagents and methods
1232013015677106/20/13Fdf03 antibodies and uses thereof
1242013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1252013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1262013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1272013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1282013013104105/23/13Spirocyclic compounds
1292013013104205/23/13Spiroxazolidinone compounds
1302013013104105/23/13Spirocyclic compounds
1312013013104205/23/13Spiroxazolidinone compounds
1322013012200905/16/13Engineered anti-il-23p19 antibodies
1332013012320005/16/13Mammalian cell surface antigens; related reagents
1342013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1352013012200905/16/13Engineered anti-il-23p19 antibodies
1362013012320005/16/13Mammalian cell surface antigens; related reagents
1372013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1382013011522305/09/13Antagonists of pcsk9
1392013011623105/09/13Tyrosine kinase inhibitors
1402013011522305/09/13Antagonists of pcsk9
1412013011623105/09/13Tyrosine kinase inhibitors
1422013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1432013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1442013007139003/21/13Method for preparing antibodies having improved properties
1452013006481703/14/13Engineered anti-il-23r antibodies
1462013005985003/07/13Aza-indole derivatives useful as modulators of faah
1472013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1482013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1492013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1502013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1512013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1522013003531202/07/13Cathepsin cysteine protease inhibiors
1532013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1542013001804801/17/13Oxazole derivatives useful as modulators of faah
1552013001252601/10/13Oxazole derivatives useful as modulators of faah
1562013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1572013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1582012032967912/27/12Eukaryotic cell display systems
1592012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1602012031620012/13/12Pyridone derivatives
1612012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1622012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1632012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1642012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1652012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1662012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1672012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1682012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1692012019690108/02/12Tertiary amide orexin receptor antagonists
1702012019070107/26/12Renin inhibitors
1712012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1722012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1732012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1742012016415806/28/12Anti-addl monoclonal antibody and use thereof
1752012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1762012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1772012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1782012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1792012014275206/07/12Hiv protease inhibitors
1802012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1812012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1822012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1832012012150805/17/12Radiolabeled cgrp antagonists
1842012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1852012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1862012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1872012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1882012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1892012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1902012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1912012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1922012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1932012008348304/05/12Inhibitors of hepatitis c virus replication
1942012008267904/05/12Antagonists of pcsk9
1952012008268004/05/12Antagonists of pcsk9
1962012007679903/29/12Antagonists of pcsk9
1972012007796403/29/12Antagonists of pcsk9
1982012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
1992012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2002012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2012012003521402/09/12Renin inhibitors
2022012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2032012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2042012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2052012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2062012002107401/26/12P2x3, receptor antagonists for treatment of pain
2072012002194801/26/12Surface display of whole antibodies in eukaryotes
2082012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2092012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2102012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2112012000958001/12/12Methods for quantitating small rna molecules
2122012001019301/12/12Cgrp receptor antagonists
2132012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2142012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2152012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2162012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2172011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2182011030107912/08/11Neuromedin u receptor agonists and uses thereof
2192011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2202011029473512/01/11Mechanism of neuromedin u action and uses thereof
2212011029477712/01/11Beta-lactamase inhibitors
2222011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2232011025059110/13/11Method of designing sirnas for gene silencing
2242011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2252011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2262011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2272011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2282011023049809/22/11Biaryl carboxamides
2292011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2302011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2312011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2322011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2332011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2342011021820209/08/11Soluble guanylate cyclase activators
2352011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2362011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2372011020162108/18/11Angiotensin ii receptor antagonists
2382011019595708/11/11Substituted diazepan orexin receptor antagonists
2392011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2402011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2412011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2422011017811707/21/11Oxazolobenzimidazole derivatives
2432011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2442011017220507/14/11Monocyclic amide cgrp receptor antagonists
2452011015230406/23/11Spiroazaindoles
2462011013676906/09/11Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
2472011012466105/26/11Oxazolobenzimidazole derivatives
2482011011833705/19/11Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
2492011011197605/12/11Microrna biomarkers of tissue injury


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo